UCB Aims High In Hidradenitis Suppurativa After Bimzelx Success
Set To Challenge Humira In Skin Disease
Topline results from two Phase III studies show the Belgian group's dual IL-17A and IL-17F inhibitor met its primary and secondary endpoints ahead of a filing for hidradenitis suppurativa next year. How well it compares with Humira and Cosentyx in this indication remains to be seen, however.
You may also be interested in...
Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.
UCB Holds Breath Amid Concerns Of Second FDA Rejection Of Bimzelx
The US Food and Drug Administration has published a report after an inspection of UCB’s Belgian facility where Bimzelx is manufactured and the findings suggest that a long-awaited approval for the psoriasis drug should not be taken for granted.
Novartis Committed To Carving Out More Indications For Cosentyx
The Swiss behemoth’s chief commercial officer Marie-France Tschudin tells Scrip that the firm will keep expanding Cosentyx into disease areas “that have been a little bit neglected.”